Psychoneuroendocrinology
Volume 28, Issue 1 , Pages 101-112 , January 2003

Effects of long-term estrogen replacement therapy on growth hormone response to pyridostigmine in healthy postmenopausal women

  • T van Amelsvoort

      Affiliations

    • Department of Psychological Medicine, Institute of Psychiatry, London, UK
    • Corresponding Author InformationCorresponding author. Present address: Department of Psychiarty, Academic Medical Centre, Tafelbergweg 25, Amsterdam 1105 BC, Holland. Tel.: +31-205667268; fax: +31-206919139
    • ,
  • D.G.M Murphy

      Affiliations

    • Department of Psychological Medicine, Institute of Psychiatry, London, UK
    • ,
  • D Robertson

      Affiliations

    • Department of Psychological Medicine, Institute of Psychiatry, London, UK
    • ,
  • E Daly

      Affiliations

    • Department of Psychological Medicine, Institute of Psychiatry, London, UK
    • ,
  • M Whitehead

      Affiliations

    • The Menopause Clinic (MW), King’s College Hospital, London, UK
    • ,
  • K Abel

      Affiliations

    • Department of Psychological Medicine, Institute of Psychiatry, London, UK

Received 17 August 2001 ,Revised 19 December 2001 ,Accepted 11 January 2002.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. Fourth ed.. Washington DC: American Psychiatric Association; 1994;
  2. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al. Gender differences in the incidence in the incidence of AD and vascular dementia. Neurology. 1999;53:1992–1997
  3. Anderson SM, Shah N, Evans WS, Patrie JT, Bowers CY, Veldhuis JD. Short-term estradiol supplementation augments growth hormone secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 2001;86:551–560
  4. Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, et al. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women. J. Clin. Endocrinol. Metab. 1993;76:374–377
  5. Arvat E, Ramunni J, Bellone J, Di Vito L, Baffoni C, Broglio F, et al. Oestrogen replacement does not restore the reduced GH-releasing activity of hexarelin, a synthetic hexapeptide in postmenopausal women, Eur. J. Endocrinol. 1997;136:483–487
  6. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2637–2641
  7. Barrett-Connor E. Hormone replacement therapy. BMJ. 1998;317:457–461
  8. Behl C. Alzheimer’s disease and oxidative stress implications for novel therapeutic approaches. Prog. Neurobiol. 1999;57:301–323
  9. Cleare AJ, Murray RM, O’Keane V. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Neuropsychopharmacology. 1996;14:349–354
  10. Coiro V, Caffari G, Volpi R, Davoli C, Capretti L, Chiodera P. Age-dependent decrease in the growth hormone response to growth hormone releasing hormone in normally cycling women. Fertil. Steril. 1996;66:230–234
  11. Cordido F, Dieguez C, Casanueva FF. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycaemia in normal and obese subjects. J. Clin. Endocrinol. Metab. 1990;70:1361–1370
  12. Corpas E, Harman SH, Blackman MR. Human growth hormone and aging. Endocr. Rev. 1993;14:20–39
  13. Coyle JT, Price DL, Relong MR. Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science. 1983;219:1184–1190
  14. Dawson-Hughes B, Stern D, Goldman J, Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J. Clin. Endocrinol. Metab. 1986;63:424–432
  15. Devesa J, Lima L, Tresguerras JAF. Neuroendocrine control of growth hormone secretion in humans. Trends Endocrinol. Metab. 1992;3:173–183
  16. Dinan TG, O’Keane V, Thakore J. Pyridostigmine-induced growth hormone release in mania: focus on cholinergic/somatostatin system. Clin. Endocrinol. 1992;40:93–96
  17. Folstein MF, Folstein SE, McHugh PR. ‘Mini Mental State’: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189–198
  18. Gibbs RB. Estrogen and nerve growth factor-related systems in brain. Ann. N.Y. Acad. Sci. 1994;14:165–199
  19. Gibbs RB. Effects of gonadal hormone replacement therapy on measures of basal forebrain cholinergic function. Neuroscience. 2000;101:931–938
  20. Ghigo E, Goffi S, Arvat E, Imperiale E, Boffano GM, Valetto MR, et al. A neuroendocrinological approach to evidence of an impairment of central cholinergic function in aging. J. Endocrinol. Invest. 1992;15:665–670
  21. Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, et al. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. Acta Endocrinol. 1990;123:169–174
  22. Ghigo E, Arvat E, Goffi S, et al.  Neural control of growth hormone secretion in aged humans. Growth Hormone and Somatomedins during Lifespan. Berlin: Springer; 1993; (pp. 275-287)
  23. Giustina A, Bossoni S, Cimino A, Pizzocolo G, Romanelli G, Wehrenberg WB. Impaired growth hormone (GH) responses to pyridostigmine in type 1 diabetic patients with exaggerated GHRH-GH-stimulated GH secretion. J. Clin. Endocrinol. Metab. 1990;71:1486–1490
  24. Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer’s disease greater for women than for men?. Am. J. Epidemiol. 2001;153:132–136
  25. Henderson V, Paganini-Hill A, Emanuel C, Dunn M, Buckwalter J. Estrogen replacement therapy in older women. Arch. Neurol. 1994;51:896–900
  26. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295–301
  27. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J. Clin. Endocrinol. Metab. 1987;64:51–58
  28. Honjo H, Tanaka K, Kashiwagi T, Urabe M, Okada H, Hayashi M, et al. Senile dementia—Alzheimer’s type and estrogen. Horm. Metab. Res. 1995;27:204–207
  29. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485–512
  30. Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50:368–373
  31. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517–1521
  32. Lang I, Schernthaner G, Pietschmann P, Kurz R, Stephenson JM, Templ H. Effects of sex and age on growth hormone response to growth hormone-releasing hormone in healthy individuals. J. Clin. Endocrinol. Metab. 1987;65:535–540
  33. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54:S4–S9
  34. Locatelli V, Torsello A, Redaelli E, Ghigo E, Massara F, Muller EE. Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin. J. Endocrinol. 1986;111:271–278
  35. Lucey JV, O’Keane V, O’Flynn K, Clare AW, Dinan TG. Gender and age differences in the growth hormone response to pyridostigmine. Int. Clin. Psychopharmacol. 1991;6:105–109
  36. Luine V, McEwen BS. Effects of an estrogen antagonist on enzyme activities and 3H-estradiol nuclear binding in uterus, pituitary, and brain. Endocrinology. 1977;100:903–910
  37. Luine V. Estradiol increases Choline Acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp. Neurol. 1985;89:484–490
  38. Luine V, Park D, Tonge J, Reis D, McEwen B. Immunochemical demonstration of increased choline acetyltransferase concentration in preoptic area after estradiol administration. Brain Res. 1980;191:273–277
  39. Maki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly estrogen users. Am. J. Psychiatry. 2001;158:227–233
  40. Massara F, Ghigo E, Molinatti P, Mazza E, Locatelli V, Muller EE, et al. Potentiation of cholinergic tone by pyridostigmine bromide reinstates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man. Acta Endocrinol. 1986;113:12–16
  41. Massara F, Ghigo E, Demislis K, Tangolo D, Mazza E, Locatelli V, et al. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects. Neuroendocrinology. 1986;43:670–675
  42. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain implications for cognition and ageing. Neurology. 1997;48:S14–S18
  43. Muller EE, Rolla M, Ghigo E, Belliti D, Arvat E, Andreoni A, et al. Involvement of brain catecholamine and acetylcholine in growth hormone hypersecretory states. Drugs. 1995;50:805–837
  44. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA. 2000;283:1007–1015
  45. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr. J. 1994;41:361–371
  46. O’Keane V, O’Flynn K, Lucey JV, Dinan TG. Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity on depression. Psychol. Med. 1992;22:55–60
  47. O’Keane V, Abel K, Murray R. Growth hormone response to pyridostigmine in schizophrenia: evidence for cholinergic dysfunction. Biol. Psychiatry. 1994;36:582–588
  48. O’Keane V, Dinan T. Sex steroid priming effects on growth hormone response to pyridostigmine throughout the menstrual cycle. J. Clin. Endocrinol. Metab. 1992;75:11–14
  49. Rainbow TC, Degroff V, Luine VN, McEwen BS. Estradiol 17 β increases the number of muscarinic receptors in hypothalamic nuclei. Brain Res. 1980;198:239–243
  50. Resnick SM, Metter EJ, Zondermann AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect?. Neurology. 1997;49:1491–1497
  51. Ross RJ, Tsagarakis S, Grossman A, Nhagafoong L, Touzel RJ, Rees LH, et al. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clin. Endocrinol. 1987;27:727–733
  52. Smith YR, Minoshima S, Kuhl DE, Zubieta JK. Effects of long-term hormone replacement therapy on cholinergic synaptic concentrations in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 2001;86:679–684
  53. Tang M, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effects of oestrogen during menopause on risk and age at onset of Alzheimer’ disease. Lancet. 1996;348:429–432
  54. Toran-Allerand CD, Miranda RC, Bentham WD, Sohrabji F, Brown TJ, Hochberg RB, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Nat. Acad. Sci. USA. 1992;89:4668–4672
  55. Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54:2061–2066
  56. Wechsler D. Wechsler Adult Intelligence Scale—Revised. New York, NY: Psychological Corporation, Harcourt Brace; 1987;
  57. White P, Hiley C, Goodhardt MJ. Neocortical cholinergic neurons in elderly people. Lancet. 1997;I:668–671
  58. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nature Med. 1998;4:447–451

PII: S0306-4530(02)00012-4

Psychoneuroendocrinology
Volume 28, Issue 1 , Pages 101-112 , January 2003

Article Tools

* Image Usage & Resolution